Wuhan General Group (China), Inc. (WUHN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerWuhan General Group (China), Inc. (WUHN) trades at $0.0002. Wuhan General Group (China), Inc. is a nutraceutical biotechnology company focused on plant-based cannabinoids and psilocybin research for medical applications. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for WUHN: WUHN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Wuhan General Group (China), Inc. (WUHN) Healthcare & Pipeline Overview
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company specializing in plant-based cannabinoids and psilocybin research, targeting medical applications like cancer and mental disorders. Operating in the specialty & generic drug manufacturing sector, the company is headquartered in Reno, Nevada, focusing on alternative medical solutions.
What Is the Investment Thesis for WUHN?
Wuhan General Group (China), Inc. presents a speculative investment opportunity within the nutraceutical biotechnology sector. The company's focus on plant-based cannabinoids and psilocybin research positions it to capitalize on the growing interest in alternative medical treatments. However, the company's negative profit margin of -13.2% and negative ROE of -8.8% indicate financial challenges. The high debt-to-equity ratio of 110.68 suggests a leveraged financial structure, increasing risk. Growth catalysts include potential regulatory approvals for cannabinoid and psilocybin-based treatments, expansion into new geographic markets, and successful clinical trials demonstrating the efficacy of its products. The company's negative free cash flow of $-0.00B highlights the need for careful monitoring of its financial performance. Investors may want to evaluate the high beta of -3.56, indicating high volatility relative to the market. The absence of a dividend yield further emphasizes the speculative nature of this investment. As of March 16, 2026, the investment thesis hinges on the company's ability to overcome financial hurdles and capitalize on its unique market position.
Based on FMP financials and quantitative analysis
WUHN Key Highlights
Negative Profit Margin of -13.2% indicates financial challenges.
- Gross Margin of 18.1% reflects the profitability of the company's products after accounting for the cost of goods sold.
- Return on Equity (ROE) of -8.8% shows the company's inefficiency in generating profit from shareholders' equity.
- Debt-to-Equity Ratio of 110.68 indicates a highly leveraged financial structure.
- Beta of -3.56 suggests high volatility and a negative correlation with the market.
Who Are WUHN's Competitors?
WUHN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $6.13 | -3.31% | $114M | — |
| ZYNE Zynerba Pharmaceuticals, Inc. | $1.30 | +2.36% | $70.1M | — |
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WUHN's Key Strengths?
Focus on alternative plant-based treatments.
- Research and development capabilities in cannabinoids and psilocybin.
- Potential for innovative product development.
- Headquartered in Reno, Nevada
What Are WUHN's Weaknesses?
Negative profit margin and ROE.
- High debt-to-equity ratio.
- Dependence on regulatory approvals.
- Limited market presence.
What Are the Key Risks for WUHN?
Intense competition in the nutraceutical and biotechnology sectors.
- Evolving regulatory landscape for cannabinoids and psilocybin.
- Adverse clinical trial results.
- Economic downturn affecting consumer spending on alternative treatments.
- High debt-to-equity ratio impacting financial stability.
What Are WUHN's Competitive Advantages?
- Specialization in plant-based cannabinoids and psilocybin research.
- Proprietary formulations and intellectual property.
- Focus on scientific validation and clinical trials.
- Established relationships with distributors and healthcare providers.
What Does WUHN Do?
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company that focuses on the research and development of alternative plant-based cannabinoids and psilocybin for medical applications. The company's inception was driven by the growing demand for alternative treatments in healthcare, particularly those derived from natural sources. Over the years, Wuhan General Group has positioned itself as a player in the nutraceutical space, offering products aimed at addressing various medical conditions, including cancer, mental disorders, and chronic pain. The company's core business revolves around the development and distribution of nutraceutical products that leverage the therapeutic potential of cannabinoids and psilocybin. These products are designed to provide alternative treatment options for patients seeking relief from a range of ailments. Wuhan General Group operates primarily from its headquarters in Reno, Nevada, where it conducts research, product development, and administrative functions. Its geographic reach is focused on markets where the use of cannabinoids and psilocybin for medical purposes is permitted and regulated. Wuhan General Group differentiates itself through its commitment to alternative plant-based solutions and its focus on rigorous medical research. This approach allows the company to develop products that are both innovative and scientifically sound. While the company faces competition from other players in the nutraceutical and biotechnology sectors, its specialization in cannabinoids and psilocybin provides a unique market position. The company's future growth is tied to its ability to navigate regulatory landscapes, expand its product offerings, and establish strong partnerships within the healthcare industry.
What Products and Services Does WUHN Offer?
- Researches and develops plant-based cannabinoids for medical applications.
- Focuses on psilocybin research for treating mental disorders.
- Offers nutraceutical products for cancer treatment.
- Develops alternative treatments for chronic pain management.
- Conducts medical research to validate the efficacy of its products.
- Distributes its products to markets where cannabinoid and psilocybin use is permitted.
How Does WUHN Make Money?
- Develops and patents novel nutraceutical formulations.
- Conducts research and clinical trials to validate product efficacy.
- Partners with distributors to market and sell products.
- Generates revenue through product sales.
What Industry Does WUHN Operate In?
Wuhan General Group (China), Inc. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, evolving regulatory landscapes, and increasing demand for alternative and plant-based treatments. The global nutraceutical market is projected to reach $441.7 billion by 2026, driven by growing consumer awareness of preventive healthcare and the therapeutic benefits of natural ingredients. Wuhan General Group's focus on cannabinoids and psilocybin positions it within a niche market that is subject to specific regulatory considerations and scientific validation requirements. Competitors include both established pharmaceutical companies and emerging biotechnology firms exploring alternative treatment modalities.
Who Are WUHN's Key Customers?
- Patients seeking alternative treatments for cancer.
- Individuals with mental disorders seeking psilocybin-based therapies.
- Patients suffering from chronic pain looking for natural relief.
- Healthcare providers recommending alternative treatments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Wuhan General Group (China), Inc. operates in the Healthcare sector. It is headquartered in Reno, US. The company is led by CEO Jeff Robinson. WUHN has traded publicly since 2006.
WUHN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
WUHN Latest News
No recent news available for WUHN.
WUHN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for WUHN.
Price Targets
Wall Street price target analysis for WUHN.
WUHN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for WUHN; grades run from A+ (80-100) to F (below 30).
WUHN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Wuhan General Group (China), Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, lower trading volume, and less stringent disclosure requirements. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility. These companies are not required to be SEC reporting.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can lead to significant price volatility.
- Potential for fraud or manipulation is higher on the OTC Other tier due to less regulatory oversight.
- Companies may have difficulty raising capital due to their listing on the OTC Other tier.
- Delisting risk is higher, which could result in the loss of investment.
- Verify the company's legal status and registration.
- Review available financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the regulatory risks associated with the company's industry.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Company has a functional website with detailed information about its products and services.
- Company provides contact information and responds to inquiries promptly.
- Company has a clear business plan and strategy.
- Company has a history of operations, even if limited.
- Company has a verifiable physical address.
WUHN Healthcare Stock FAQ
What do analysts say about WUHN stock?
As of March 16, 2026, there is no available analyst coverage for Wuhan General Group (China), Inc. due to its OTC Other listing and limited market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.